JP2018154628A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018154628A5 JP2018154628A5 JP2018088769A JP2018088769A JP2018154628A5 JP 2018154628 A5 JP2018154628 A5 JP 2018154628A5 JP 2018088769 A JP2018088769 A JP 2018088769A JP 2018088769 A JP2018088769 A JP 2018088769A JP 2018154628 A5 JP2018154628 A5 JP 2018154628A5
- Authority
- JP
- Japan
- Prior art keywords
- amino acid
- acid sequence
- polypeptide
- seq
- disease
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 229920001184 polypeptide Polymers 0.000 claims 21
- 125000003275 alpha amino acid group Chemical group 0.000 claims 19
- 150000001413 amino acids Chemical class 0.000 claims 5
- 102100015975 IL17F Human genes 0.000 claims 4
- 101700007032 IL17F Proteins 0.000 claims 4
- 201000010099 disease Diseases 0.000 claims 4
- 238000002198 surface plasmon resonance spectroscopy Methods 0.000 claims 4
- 101000408055 IL17A Proteins 0.000 claims 3
- 201000005794 allergic hypersensitivity disease Diseases 0.000 claims 3
- 102000028356 human IL17A protein Human genes 0.000 claims 3
- 206010020751 Hypersensitivity Diseases 0.000 claims 2
- 102000018358 Immunoglobulins Human genes 0.000 claims 2
- 108060003951 Immunoglobulins Proteins 0.000 claims 2
- 206010029240 Neuritis Diseases 0.000 claims 2
- 230000003210 demyelinating Effects 0.000 claims 2
- 230000009610 hypersensitivity Effects 0.000 claims 2
- 230000001404 mediated Effects 0.000 claims 2
- 230000002269 spontaneous Effects 0.000 claims 2
- 208000009094 Anemia, Hemolytic, Autoimmune Diseases 0.000 claims 1
- 208000006673 Asthma Diseases 0.000 claims 1
- 206010003827 Autoimmune hepatitis Diseases 0.000 claims 1
- 206010050245 Autoimmune thrombocytopenia Diseases 0.000 claims 1
- 210000000941 Bile Anatomy 0.000 claims 1
- 210000003169 Central Nervous System Anatomy 0.000 claims 1
- 206010008609 Cholangitis sclerosing Diseases 0.000 claims 1
- 208000004275 Demyelinating Disease Diseases 0.000 claims 1
- 206010012438 Dermatitis atopic Diseases 0.000 claims 1
- 206010012601 Diabetes mellitus Diseases 0.000 claims 1
- 206010015150 Erythema Diseases 0.000 claims 1
- 208000004262 Food Hypersensitivity Diseases 0.000 claims 1
- 206010016946 Food allergy Diseases 0.000 claims 1
- 102220385926 GLO1 I86A Human genes 0.000 claims 1
- 102220379712 GLO1 L74A Human genes 0.000 claims 1
- 108010068370 Glutens Proteins 0.000 claims 1
- 208000002183 Guillain-Barre Syndrome Diseases 0.000 claims 1
- 206010019641 Hepatic cirrhosis Diseases 0.000 claims 1
- 206010061218 Inflammation Diseases 0.000 claims 1
- 206010021972 Inflammatory bowel disease Diseases 0.000 claims 1
- 208000003456 Juvenile Arthritis Diseases 0.000 claims 1
- 206010028640 Myopathy Diseases 0.000 claims 1
- 206010029151 Nephropathy Diseases 0.000 claims 1
- 102200007756 PPIE R47A Human genes 0.000 claims 1
- 210000001428 Peripheral Nervous System Anatomy 0.000 claims 1
- 206010035664 Pneumonia Diseases 0.000 claims 1
- 208000005069 Pulmonary Fibrosis Diseases 0.000 claims 1
- 208000002098 Purpura, Thrombocytopenic, Idiopathic Diseases 0.000 claims 1
- 102200143370 RNF13 N88A Human genes 0.000 claims 1
- 206010038428 Renal disease Diseases 0.000 claims 1
- 206010039073 Rheumatoid arthritis Diseases 0.000 claims 1
- 206010039085 Rhinitis allergic Diseases 0.000 claims 1
- 102200111777 SLC11A2 N89A Human genes 0.000 claims 1
- 208000010157 Sclerosing Cholangitis Diseases 0.000 claims 1
- 210000003491 Skin Anatomy 0.000 claims 1
- 208000006641 Skin Disease Diseases 0.000 claims 1
- 208000004732 Systemic Vasculitis Diseases 0.000 claims 1
- 206010042953 Systemic sclerosis Diseases 0.000 claims 1
- 102220386422 TDP1 Y85A Human genes 0.000 claims 1
- 206010043778 Thyroiditis Diseases 0.000 claims 1
- 208000002474 Tinea Diseases 0.000 claims 1
- 206010052779 Transplant rejections Diseases 0.000 claims 1
- 241000893966 Trichophyton verrucosum Species 0.000 claims 1
- 206010046736 Urticarias Diseases 0.000 claims 1
- 206010047931 Whipple's disease Diseases 0.000 claims 1
- 201000010105 allergic rhinitis Diseases 0.000 claims 1
- 201000008937 atopic dermatitis Diseases 0.000 claims 1
- 230000001363 autoimmune Effects 0.000 claims 1
- 201000000448 autoimmune hemolytic anemia Diseases 0.000 claims 1
- 201000006322 bullous skin disease Diseases 0.000 claims 1
- 230000001684 chronic Effects 0.000 claims 1
- 238000010494 dissociation reaction Methods 0.000 claims 1
- 230000005593 dissociations Effects 0.000 claims 1
- 201000009580 eosinophilic pneumonia Diseases 0.000 claims 1
- 231100000321 erythema Toxicity 0.000 claims 1
- 235000021312 gluten Nutrition 0.000 claims 1
- 201000007192 granulomatous hepatitis Diseases 0.000 claims 1
- 201000010229 hepatobiliary disease Diseases 0.000 claims 1
- 230000002458 infectious Effects 0.000 claims 1
- 230000002757 inflammatory Effects 0.000 claims 1
- 230000004054 inflammatory process Effects 0.000 claims 1
- 238000003780 insertion Methods 0.000 claims 1
- 201000004044 liver cirrhosis Diseases 0.000 claims 1
- 201000006417 multiple sclerosis Diseases 0.000 claims 1
- 201000010770 muscular disease Diseases 0.000 claims 1
- 201000009623 myopathy Diseases 0.000 claims 1
- 201000008482 osteoarthritis Diseases 0.000 claims 1
- 239000000546 pharmaceutic aid Substances 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 201000000306 sarcoidosis Diseases 0.000 claims 1
- 238000006467 substitution reaction Methods 0.000 claims 1
- 201000010874 syndrome Diseases 0.000 claims 1
- 201000000596 systemic lupus erythematosus Diseases 0.000 claims 1
- 201000009594 systemic scleroderma Diseases 0.000 claims 1
- 238000002054 transplantation Methods 0.000 claims 1
Claims (10)
- 少なくとも１つの第一の免疫グロブリン単一可変ドメイン（ＩＳＶ）および少なくとも１つの第二の免疫グロブリン単一可変ドメイン（ＩＳＶ）を含むポリペプチドであって、ヒトのIL-17A、ヒトのIL-17Fおよび／またはヒトのIL-17A/Fに特異的に結合し、
ここで、第一のＩＳＶは、
ａ）（ｉ）アミノ酸配列SYVVG（配列番号２２２）または（ｉｉ）アミノ酸配列SYVVG（配列番号２２２）と１個のアミノ酸相違しか有さないアミノ酸配列のいずれかであるCDR1；
ｂ）（ｉ）アミノ酸配列AISGSGDSIYYAVSEKD（配列番号３６４）または（ｉｉ）アミノ酸配列AISGSGESIYYAVSEKG（配列番号３６４）と３個までのアミノ酸相違しか有さないアミノ酸配列のいずれかであるCDR2；および
ｃ）（ｉ）アミノ酸配列DQEFGYLRFGRSEY（配列番号５０６）または（ｉｉ）アミノ酸配列DQEFGYLRFGRSEY（配列番号５０６）と３個までのアミノ酸相違しか有さないアミノ酸配列のいずれかであるCDR3；
を含み、および、
第二のＩＳＶが、
ａ）アミノ酸配列AMG（配列番号２３８）を含むCDR1；
ｂ）（ｉ）アミノ酸配列AISGSGDDTYYADSVKG（配列番号３８０）または（ｉｉ）アミノ酸配列AISATGDDTYYADSVKG（配列番号３８０）と３個までのアミノ酸相違しか有さないアミノ酸配列のいずれかを含むCDR2；および
ｃ）（ｉ）アミノ酸配列RRGLYYVWDSNDYEN（配列番号５２２）または（ｉｉ）アミノ酸配列RRGLYYVWDANDYEN（配列番号５２２）と３個までのアミノ酸相違しか有さないアミノ酸配列のいずれかを含むCDR3
を含む、前記ポリペプチド。 - 請求項１に記載のポリペプチドであって、前記の特異的結合が、表面プラズモン共鳴（ＳＰＲ）によって測定される場合、１０ -３ ｓ -1 〜１０ -6 ｓ -1 の解離速度（ｋ off 速度）を特徴とする前記ポリペプチド。
- 請求項１または２に記載のポリペプチドであって、前記の特異的結合が、表面プラズモン共鳴（ＳＰＲ）によって測定される場合、１ｎＭ未満のＫ D で生ずる前記ポリペプチド。
- 請求項１から３までのいずれか１項に記載のポリペプチドであって、前記のポリペプチドは、軽鎖可変ドメイン、重鎖可変ドメインおよび／または単一可変ドメインを含む、前記ポリペプチド。
- 請求項１から４までのいずれか１項に記載のポリペプチドであって、前記のポリペプチドは、野生型のヒトIL-17F配列への結合と比較して大きく低減された親和性でIL-17F突然変異体へ結合し、IL-17F突然変異体は、R47A、I86AおよびN89Aの１以上を含む、前記ポリペプチド。
- 請求項１から５までのいずれか１項に記載のポリペプチドであって、前記のポリペプチドは、野生型のヒトIL-17A配列への結合と比較して大きく低減された親和性でIL-17F突然変異体へ結合し、IL-17F突然変異体は、L74A、Y85AおよびN88Aの１以上を含む、前記ポリペプチド。
- 請求項１から６までのいずれか１項に記載のポリペプチドであって、前記のポリペプチドは、配列番号８３６のアミノ酸配列において、１個から１０個までのアミノ酸置換、欠失、および／または挿入を含んでいる、前記ポリペプチド。
- 配列番号８３６のアミノ酸配列を含む、請求項１から７のいずれか１項に記載のポリペプチド。
- 請求項１から８までのいずれか１項に記載のポリペプチドであって、全身性エリテマトーデス、リウマチ様関節炎、変形性関節症、若年性慢性関節炎、脊椎関節症、全身性硬化症、突発性炎症性筋疾患、シェーグレン症候群、全身性血管炎、サルコイドーシス、自己免疫性溶血性貧血、自己免疫性血小板減少症、甲状腺炎、糖尿病、免疫介在性腎疾患、中枢神経系および末梢神経系の脱髄疾患、多発性硬化症、突発性脱髄性多発根神経炎、ギラン・バレー症候群、慢性炎症性脱髄性多発根神経炎、肝胆道系疾患、感染性自己免疫性慢性活動性肝炎、原発性胆汁性肝硬変、肉芽腫性肝炎、硬化性胆管炎、炎症性腸疾患、グルテン過敏性腸疾患、ウィップル病、自己免疫性もしくは免疫介在性の皮膚病、水疱性皮膚病、多形性紅斑、接触皮膚炎、乾癬、アレルギー疾患、喘息、アレルギー性鼻炎、アトピー性皮膚炎、食物過敏症、蕁麻疹、好酸球性肺炎、突発性肺線維症、過敏性肺炎、移植関連疾患、移植片拒絶および移植片対宿主病からなる群より選択される疾患または障害の治療のための前記ポリペプチド。
- 請求項１から８までのいずれか１項に記載のポリペプチドと製剤学的に認容性の賦形剤とを含む医薬組成物。
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161482802P | 2011-05-05 | 2011-05-05 | |
| US61/482,802 | 2011-05-05 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014508842A Division JP6628965B2 (ja) | 2011-05-05 | 2012-05-04 | Ｉｌ−１７ａ、ｉｌ−１７ｆおよび／またはｉｌ１７−ａ／ｆに対するアミノ酸配列および前記アミノ酸配列を含むポリペプチド |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020084866A Division JP7093380B2 (ja) | 2011-05-05 | 2020-05-14 | Ｉｌ－１７ａ、ｉｌ－１７ｆおよび／またはｉｌ１７－ａ／ｆに対するアミノ酸配列および前記アミノ酸配列を含むポリペプチド |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2018154628A JP2018154628A (ja) | 2018-10-04 |
| JP2018154628A5 true JP2018154628A5 (ja) | 2019-04-25 |
| JP6768027B2 JP6768027B2 (ja) | 2020-10-14 |
Family
ID=46245559
Family Applications (5)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014508842A Active JP6628965B2 (ja) | 2011-05-05 | 2012-05-04 | Ｉｌ−１７ａ、ｉｌ−１７ｆおよび／またはｉｌ１７−ａ／ｆに対するアミノ酸配列および前記アミノ酸配列を含むポリペプチド |
| JP2018088769A Active JP6768027B2 (ja) | 2011-05-05 | 2018-05-02 | Ｉｌ−１７ａ、ｉｌ−１７ｆおよび／またはｉｌ１７−ａ／ｆに対するアミノ酸配列および前記アミノ酸配列を含むポリペプチド |
| JP2020084866A Active JP7093380B2 (ja) | 2011-05-05 | 2020-05-14 | Ｉｌ－１７ａ、ｉｌ－１７ｆおよび／またはｉｌ１７－ａ／ｆに対するアミノ酸配列および前記アミノ酸配列を含むポリペプチド |
| JP2022097718A Pending JP2022137058A (ja) | 2011-05-05 | 2022-06-17 | Ｉｌ－１７ａ、ｉｌ－１７ｆおよび／またはｉｌ１７－ａ／ｆに対するアミノ酸配列および前記アミノ酸配列を含むポリペプチド |
| JP2024083267A Pending JP2024122989A (ja) | 2011-05-05 | 2024-05-22 | Ｉｌ－１７ａ、ｉｌ－１７ｆおよび／またはｉｌ１７－ａ／ｆに対するアミノ酸配列および前記アミノ酸配列を含むポリペプチド |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014508842A Active JP6628965B2 (ja) | 2011-05-05 | 2012-05-04 | Ｉｌ−１７ａ、ｉｌ−１７ｆおよび／またはｉｌ１７−ａ／ｆに対するアミノ酸配列および前記アミノ酸配列を含むポリペプチド |
Family Applications After (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020084866A Active JP7093380B2 (ja) | 2011-05-05 | 2020-05-14 | Ｉｌ－１７ａ、ｉｌ－１７ｆおよび／またはｉｌ１７－ａ／ｆに対するアミノ酸配列および前記アミノ酸配列を含むポリペプチド |
| JP2022097718A Pending JP2022137058A (ja) | 2011-05-05 | 2022-06-17 | Ｉｌ－１７ａ、ｉｌ－１７ｆおよび／またはｉｌ１７－ａ／ｆに対するアミノ酸配列および前記アミノ酸配列を含むポリペプチド |
| JP2024083267A Pending JP2024122989A (ja) | 2011-05-05 | 2024-05-22 | Ｉｌ－１７ａ、ｉｌ－１７ｆおよび／またはｉｌ１７－ａ／ｆに対するアミノ酸配列および前記アミノ酸配列を含むポリペプチド |
Country Status (24)
| Country | Link |
|---|---|
| US (4) | US10017568B2 (ja) |
| EP (3) | EP4105231A1 (ja) |
| JP (5) | JP6628965B2 (ja) |
| KR (1) | KR102083230B1 (ja) |
| CN (2) | CN107098971B (ja) |
| AU (1) | AU2012257942B8 (ja) |
| BR (1) | BR112013028407B1 (ja) |
| CA (1) | CA2834907C (ja) |
| CL (1) | CL2013003090A1 (ja) |
| DK (1) | DK2705058T3 (ja) |
| EA (1) | EA035973B9 (ja) |
| ES (1) | ES2662371T3 (ja) |
| HR (1) | HRP20180380T1 (ja) |
| HU (1) | HUE037225T2 (ja) |
| IL (1) | IL228813B (ja) |
| LT (1) | LT2705058T (ja) |
| MX (1) | MX2013012844A (ja) |
| MY (1) | MY167231A (ja) |
| NZ (1) | NZ616761A (ja) |
| PT (1) | PT2705058T (ja) |
| SG (2) | SG10201606409TA (ja) |
| SI (1) | SI2705058T1 (ja) |
| UA (1) | UA117218C2 (ja) |
| WO (1) | WO2012156219A1 (ja) |
Families Citing this family (41)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2011254557B2 (en) | 2010-05-20 | 2015-09-03 | Ablynx Nv | Biological materials related to HER3 |
| UA117218C2 (uk) | 2011-05-05 | 2018-07-10 | Мерк Патент Гмбх | Поліпептид, спрямований проти il-17a, il-17f та/або il17-a/f |
| WO2014076321A1 (en) * | 2012-11-19 | 2014-05-22 | Pieris Ag | Novel specific-binding polypeptides and uses thereof |
| FR3007411B1 (fr) * | 2013-06-21 | 2015-07-03 | Agronomique Inst Nat Rech | Anticorps monocatenaire a chaine lourde de camelide dirige contre la chromatine et utilisations |
| CA2937556A1 (en) | 2014-02-21 | 2015-08-27 | Genentech, Inc. | Anti-il-13/il-17 bispecific antibodies and uses thereof |
| CA2948076A1 (en) | 2014-05-16 | 2015-11-19 | Ablynx Nv | Improved immunoglobulin variable domains |
| MX2016015235A (es) | 2014-05-22 | 2017-06-29 | Pieris Pharmaceuticals Gmbh | Nuevos polipeptidos de union especifica y usos de los mismos. |
| US20160000936A1 (en) | 2014-06-10 | 2016-01-07 | Abbvie Inc. | Biomarkers for inflammatory disease and methods of using same |
| RU2609627C2 (ru) * | 2014-09-26 | 2017-02-02 | Закрытое Акционерное Общество "Биокад" | Высокоаффинные и агрегационно стабильные антитела на основе вариабельных доменов vl и производного vhh |
| GB201500463D0 (en) * | 2015-01-12 | 2015-02-25 | Cresendo Biolog Ltd | Therapeutic molecules |
| JP7001474B2 (ja) | 2015-01-21 | 2022-01-19 | インヒブルクス，インコーポレイティド | 非免疫原性単一ドメイン抗体 |
| CN107407677B (zh) | 2015-01-28 | 2020-07-17 | 豪夫迈·罗氏有限公司 | 多发性硬化的基因表达标志和治疗 |
| KR20240156437A (ko) * | 2015-10-27 | 2024-10-29 | 유씨비 바이오파마 에스알엘 | 항-il-17a/f 항체를 사용한 치료 방법 |
| GB201522391D0 (en) * | 2015-12-18 | 2016-02-03 | Ucb Biopharma Sprl | Antibody molecules |
| RU2680011C2 (ru) * | 2016-04-29 | 2019-02-14 | Закрытое Акционерное Общество "Биокад" | Триспецифические антитела против il-17a, il-17f и другой провоспалительной молекулы |
| GB201612043D0 (en) * | 2016-07-11 | 2016-08-24 | Crescendo Biologics Ltd | Composition for treatment of disorders |
| JP6995127B2 (ja) | 2017-02-10 | 2022-02-04 | ジェネンテック， インコーポレイテッド | 抗トリプターゼ抗体、その組成物、及びその使用 |
| CN108359011B (zh) * | 2017-07-21 | 2019-06-25 | 华博生物医药技术（上海）有限公司 | 靶向于白介素17a的抗体、其制备方法和应用 |
| CN107857818A (zh) * | 2017-08-07 | 2018-03-30 | 上海科新生物技术股份有限公司 | 一种针对IL‑17和TNF‑α的双特异性融合蛋白 |
| CN113603777B (zh) * | 2018-02-12 | 2022-10-21 | 原启生物科技(上海)有限责任公司 | Il17抗体及其应用 |
| CN110003329B (zh) * | 2019-04-12 | 2022-09-27 | 深圳普瑞金生物药业股份有限公司 | 多肽、il17a/f单域抗体、核苷酸序列及试剂盒 |
| CN113603765B (zh) * | 2020-07-15 | 2024-05-14 | 百奥赛图(北京)医药科技股份有限公司 | Il17f基因人源化的非人动物及其构建方法和应用 |
| WO2022040506A2 (en) * | 2020-08-21 | 2022-02-24 | Yale University | Nanobody compositions and methods of use of the same |
| WO2023035272A1 (zh) * | 2021-09-13 | 2023-03-16 | 深圳华普药物研发有限公司 | 一种il17抗体及其制备方法和应用 |
| CN114380906B (zh) * | 2022-03-25 | 2022-06-14 | 南京融捷康生物科技有限公司 | 一种抗il-17a的单域抗体及其用途 |
| WO2023186174A1 (en) * | 2022-04-01 | 2023-10-05 | Zai Lab (Shanghai) Co., Ltd. | Topical formulation comprising an il-17a binding molecule and uses thereof |
| WO2023203549A1 (en) | 2022-04-22 | 2023-10-26 | Moonlake Immunotherapeutics Ag | Methods of achieving safe and sustained control of il-17-dependent conditions in subjects responsive to treatment with an anti-il 17a/f nanobody |
| CN115093483A (zh) * | 2022-06-17 | 2022-09-23 | 国药中生生物技术研究院有限公司 | Il-17ra融合蛋白、药物组合物、注射剂及其应用 |
| WO2024133935A1 (en) | 2022-12-23 | 2024-06-27 | Ablynx Nv | Protein-based conjugation carriers |
| EP4393948A1 (en) | 2022-12-28 | 2024-07-03 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. | Therapeutic vhh antibodies cross-neutralizing the il-17a and il-17f homodimers as well as the il-17af heterodimer |
| US20240368250A1 (en) | 2023-02-17 | 2024-11-07 | Ablynx N.V. | Polypeptides binding to the neonatal fc receptor |
| CN116769027B (zh) * | 2023-06-09 | 2023-12-01 | 康元医疗科技(大连)有限公司 | 一种抗il-17纳米抗体、多肽及其应用 |
| CN117843776B (zh) * | 2023-12-21 | 2024-08-30 | 北京贝来药业有限公司 | 抗体分子、核酸、制药用途及炎性疾病治疗方法 |
| CN117843804B (zh) * | 2023-12-29 | 2024-08-20 | 北京贝来药业有限公司 | 单域抗体串联分子及其序列、产品、制备和应用 |
| CN117843801B (zh) * | 2023-12-29 | 2024-08-02 | 北京贝来药业有限公司 | 以白介素家族成员为靶点的新型抗体以及下游产品 |
| CN117843805B (zh) * | 2023-12-29 | 2024-09-06 | 北京贝来药业有限公司 | 抗体分子、核酸分子、药物组合物以及应用 |
| CN117820481A (zh) * | 2023-12-29 | 2024-04-05 | 北京贝来药业有限公司 | 新型抗体分子及其制药用途 |
| CN118206654B (zh) * | 2024-03-05 | 2024-09-20 | 北京贝来药业有限公司 | 用于疾病治疗的新型抗体及其产品和应用 |
| CN117866905B (zh) * | 2024-03-12 | 2024-06-04 | 北京贝来药业有限公司 | 基于纳米抗体基因修饰的干细胞及其制备方法和产品 |
| CN117866903B (zh) * | 2024-03-12 | 2024-06-04 | 北京贝来药业有限公司 | 单域抗体修饰的干细胞及其在疾病治疗中用途 |
| CN117860786B (zh) * | 2024-03-12 | 2024-06-04 | 北京贝来药业有限公司 | 基因修饰间充质干细胞在多种疾病中的制药用途和诊断用途 |
Family Cites Families (122)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2052027T5 (es) | 1988-11-11 | 2005-04-16 | Medical Research Council | Clonacion de secuencias de dominio variable de inmunoglobulina. |
| IL162181A (en) | 1988-12-28 | 2006-04-10 | Pdl Biopharma Inc | A method of producing humanized immunoglubulin, and polynucleotides encoding the same |
| US5399346A (en) | 1989-06-14 | 1995-03-21 | The United States Of America As Represented By The Department Of Health And Human Services | Gene therapy |
| SE509359C2 (sv) | 1989-08-01 | 1999-01-18 | Cemu Bioteknik Ab | Användning av stabiliserade protein- eller peptidkonjugat för framställning av ett läkemedel |
| WO1992002551A1 (en) | 1990-08-02 | 1992-02-20 | B.R. Centre Limited | Methods for the production of proteins with a desired function |
| DE69318016D1 (de) | 1992-05-08 | 1998-05-20 | Creative Biomolecules Inc | Mehrwertige Chimäre Proteine Anologe und Verfahren zu deren Anwendungen |
| CA2137558A1 (en) | 1992-07-17 | 1994-02-03 | Wayne A. Marasco | Method of intracellular binding of target molecules |
| WO1994004678A1 (en) | 1992-08-21 | 1994-03-03 | Casterman Cecile | Immunoglobulins devoid of light chains |
| DK0702721T3 (da) | 1993-06-09 | 2001-05-21 | Unilever Nv | Fremgangsmåde til fremstilling af fusionsproteiner, der omfatter ScFv fragmenter, ved hjælp af en transformeret skimmelsvamp |
| US6562333B1 (en) | 1993-06-14 | 2003-05-13 | Schering Corporation | Purified mammalian CTLA-8 antigens and related reagents |
| US6274711B1 (en) | 1993-06-14 | 2001-08-14 | Inserm, Institut National De La Sante Et De La Recherche Medicale | Purified mammalian CTLA-8 antigens and related reagents |
| US6091639A (en) | 1993-08-27 | 2000-07-18 | Kabushiki Kaisha Toshiba | Non-volatile semiconductor memory device and data programming method |
| EP0745134A1 (en) | 1994-02-22 | 1996-12-04 | Danafarber Cancer Institute | Nucleic acid delivery system, method of synthesis and uses thereof |
| EP0739981A1 (en) | 1995-04-25 | 1996-10-30 | Vrije Universiteit Brussel | Variable fragments of immunoglobulins - use for therapeutic or veterinary purposes |
| CA2227220A1 (en) | 1995-07-19 | 1997-02-06 | Genetics Institute, Inc. | Human ctla-8 and uses of ctla-8-related proteins |
| US6074849A (en) | 1995-07-19 | 2000-06-13 | Genetics Institute, Inc. | Polynucleotides encoding human CTLA-8 related proteins |
| US6902735B1 (en) | 1995-07-19 | 2005-06-07 | Genetics Institute, Llc | Antibodies to human IL-17F and other CTLA-8-related proteins |
| AU7298398A (en) | 1996-11-19 | 1998-06-10 | Sangstat Medical Corporation | Enhanced effects for hapten conjugated therapeutics |
| US20020177188A1 (en) | 1998-05-15 | 2002-11-28 | Genentech, Inc. | IL-17 homologous polypeptides and therapeutic uses thereof |
| BR9813276A (pt) | 1997-10-27 | 2000-08-22 | Unilever Nv | Proteìna multivalente de ligação de antìgeno, sequências de nucleotìdeos, vetor de expressão, célula hospedeira, processo para preparação de proteìna multivalente de ligação de antìgeno, e, uso da mesma |
| AU3596599A (en) | 1998-01-26 | 1999-08-09 | Unilever Plc | Method for producing antibody fragments |
| CN1316910A (zh) | 1998-02-19 | 2001-10-10 | 埃克斯西特治疗公司 | 用于调节淋巴细胞活化的组合物及方法 |
| US6486303B1 (en) | 1998-04-14 | 2002-11-26 | University Of Medicine & Dentistry Of New Jersey | Method for making hormone heterodimers |
| AU6277799A (en) | 1998-10-02 | 2000-04-26 | Eli Lilly And Company | Il-17 homolog nucleic acids, polypeptides, vectors, host cells, methods and usesthereof |
| GB9824632D0 (en) | 1998-11-10 | 1999-01-06 | Celltech Therapeutics Ltd | Biological compounds |
| AU2291700A (en) | 1999-01-19 | 2000-08-07 | Unilever Plc | Method for producing antibody fragments |
| EP1053751A1 (en) | 1999-05-17 | 2000-11-22 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | Compositions and methods for treating cell proliferation disorders |
| ES2380958T3 (es) | 1999-12-23 | 2012-05-21 | Genentech, Inc. | Polipéptidos homólogos IL-17 y utilizaciones terapéuticas de los mismos |
| US7608681B2 (en) | 1999-12-24 | 2009-10-27 | Genentech, Inc. | Methods and compositions for prolonging elimination half-times of bioactive compounds |
| DK2236152T3 (da) | 2000-04-12 | 2014-07-07 | Novozymes Biopharma Dk As | Albuminfusionsproteiner |
| WO2001090190A2 (en) | 2000-05-26 | 2001-11-29 | National Research Council Of Canada | Single-domain antigen-binding antibody fragments derived from llama antibodies |
| WO2002057445A1 (en) | 2000-05-26 | 2002-07-25 | National Research Council Of Canada | Single-domain brain-targeting antibody fragments derived from llama antibodies |
| US6741957B1 (en) | 2000-07-21 | 2004-05-25 | Daimlerchrysler Corporation | Analytical tire model for vehicle durability and ride comfort analysis |
| US7829084B2 (en) | 2001-01-17 | 2010-11-09 | Trubion Pharmaceuticals, Inc. | Binding constructs and methods for use thereof |
| CA2433877C (en) | 2001-01-17 | 2014-11-18 | Genecraft, Inc. | Binding domain-immunoglobulin fusion proteins |
| AU2002242142A1 (en) | 2001-02-09 | 2002-08-28 | Johns Hopkins University | A cytokine related structurally to il-17 |
| US7211395B2 (en) | 2001-03-09 | 2007-05-01 | Dyax Corp. | Serum albumin binding moieties |
| GB0110029D0 (en) | 2001-04-24 | 2001-06-13 | Grosveld Frank | Transgenic animal |
| US20070160576A1 (en) | 2001-06-05 | 2007-07-12 | Genentech, Inc. | IL-17A/F heterologous polypeptides and therapeutic uses thereof |
| EP1399484B1 (en) | 2001-06-28 | 2010-08-11 | Domantis Limited | Dual-specific ligand and its use |
| US20060073141A1 (en) | 2001-06-28 | 2006-04-06 | Domantis Limited | Compositions and methods for treating inflammatory disorders |
| AU2002355477B2 (en) | 2001-08-03 | 2008-09-25 | Medical Research Council | Method of identifying a consensus sequence for intracellular antibodies |
| EP1433793A4 (en) | 2001-09-13 | 2006-01-25 | Inst Antibodies Co Ltd | METHOD FOR CREATING A CAMEL ANTIBODY LIBRARY |
| JP2005289809A (ja) | 2001-10-24 | 2005-10-20 | Vlaams Interuniversitair Inst Voor Biotechnologie Vzw (Vib Vzw) | 突然変異重鎖抗体 |
| KR100599789B1 (ko) | 2001-12-03 | 2006-07-12 | 삼성에스디아이 주식회사 | 방열효율이 향상된 플라즈마 디스플레이 장치 및 그 제조방법 |
| EP1456410A2 (en) | 2001-12-11 | 2004-09-15 | AlgoNomics N.V. | Method for displaying loops from immunoglobulin domains in different contexts |
| AU2002360068B2 (en) | 2001-12-21 | 2009-09-03 | Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw | Method for cloning of variable domain sequences |
| JP2005517674A (ja) | 2002-01-03 | 2005-06-16 | フラームス・インテルウニフェルシタイル・インステイチュート・フォール・ビオテヒノロヒー・ヴェーゼットウェー | 腫瘍の処置に有用な新規免疫コンジュゲート |
| US20080241166A1 (en) | 2002-06-28 | 2008-10-02 | Domantis Limited | Ligands that bind a receptor |
| ATE328906T1 (de) | 2002-06-28 | 2006-06-15 | Domantis Ltd | Dual-specifische liganden mit erhöhter halbwertszeit |
| US7004940B2 (en) | 2002-10-10 | 2006-02-28 | Ethicon, Inc. | Devices for performing thermal ablation having movable ultrasound transducers |
| AU2003283137B8 (en) | 2002-11-08 | 2010-07-29 | Ablynx N.V. | Camelidae antibodies against immunoglobulin E and use thereof for the treatment of allergic disorders |
| MXPA05004955A (es) | 2002-11-08 | 2005-11-17 | Ablynx Nv | Anticuerpos de region unica dirigidos contra el factor-alfa de necrosis de tumor y usos de estos. |
| GB0228210D0 (en) | 2002-12-03 | 2003-01-08 | Babraham Inst | Single chain antibodies |
| WO2004051268A1 (en) | 2002-12-03 | 2004-06-17 | Celltech R & D Limited | Assay for identifying antibody producing cells |
| GB0230203D0 (en) | 2002-12-27 | 2003-02-05 | Domantis Ltd | Fc fusion |
| AU2003300133B2 (en) | 2002-12-31 | 2008-11-13 | Nektar Therapeutics | Hydrolytically stable maleimide-terminated polymers |
| KR20050092029A (ko) | 2003-01-10 | 2005-09-16 | 아블린쓰 엔.브이. | 폰 빌레브란트 인자(ｖＷＦ) 또는 콜라겐에 대한낙타과로부터의 재조합 ＶＨＨ 단일 도메인 항체 |
| GB0312481D0 (en) | 2003-05-30 | 2003-07-09 | Celltech R&D Ltd | Antibodies |
| SI1639011T1 (sl) | 2003-06-30 | 2009-04-30 | Domantis Ltd | Pegilirana protitelesa z enojno domeno (dAb) |
| SI2784084T2 (sl) | 2003-07-08 | 2024-02-29 | Novartis Pharma Ag | Antagonistična protitelesa proti IL-17 A/F heterolognim polipeptidom |
| JP2007521234A (ja) | 2003-08-12 | 2007-08-02 | ウィリアム エム ヤーブロー | 尋常性ざ瘡の治療薬及び使用方法 |
| ES2385829T3 (es) | 2003-08-20 | 2012-08-01 | Ucb Pharma, S.A. | Métodos para obtener anticuerpos |
| US20050279676A1 (en) | 2004-06-21 | 2005-12-22 | Izzy Zuhair A | Fluid filter assembly for a dispensing faucet |
| US20060008601A1 (en) | 2004-06-25 | 2006-01-12 | Zeik Douglas B | Flexible laminate having an integrated pressure release valve |
| US7882839B2 (en) | 2004-06-25 | 2011-02-08 | Ambis Jr Edward J | Custom mouthguard |
| WO2006008548A2 (en) | 2004-07-22 | 2006-01-26 | Erasmus University Medical Centre Rotterdam | Binding molecules |
| CN100396019C (zh) | 2004-07-31 | 2008-06-18 | 华为技术有限公司 | 移动终端数据源模拟方法 |
| GB0417487D0 (en) | 2004-08-05 | 2004-09-08 | Novartis Ag | Organic compound |
| US7563443B2 (en) | 2004-09-17 | 2009-07-21 | Domantis Limited | Monovalent anti-CD40L antibody polypeptides and compositions thereof |
| US20080107601A1 (en) | 2004-10-13 | 2008-05-08 | Ablynx N.V. | Nanobodies Tm Against Amyloid-Beta and Polypeptides Comprising the Same for the Treatment of Degenerative Neural Diseases Such as Alzheimer's Disease |
| WO2006040154A2 (en) | 2004-10-14 | 2006-04-20 | Dublin City University | Prokaryotic two hybrid system |
| GB0425569D0 (en) * | 2004-11-19 | 2004-12-22 | Celltech R&D Ltd | Biological products |
| MY142617A (en) | 2004-12-23 | 2010-12-15 | Domantis Ltd | Dual specific ligands with increased serum half-life |
| AU2005325801A1 (en) | 2005-01-31 | 2006-08-03 | Ablynx N.V. | Method for generating variable domain sequences of heavy chain antibodies |
| MX2007009811A (es) | 2005-02-14 | 2007-09-07 | Wyeth Corp | Anticuerpos para interleucina-17f y otros antagonistas de la senalizacion de il 17f, y sus usos. |
| MX363423B (es) | 2005-05-18 | 2019-03-22 | Ablynx Nv | Nanobodiestm (nanocuerpos) mejorados contra el factor alfa de necrosis del tumor. |
| KR101414438B1 (ko) | 2005-05-20 | 2014-07-10 | 아블린쓰 엔.브이. | 폰 빌레브란트 인자에 대한 단일 도메인 ｖｈｈ 항체 |
| US20090252681A1 (en) | 2005-10-11 | 2009-10-08 | Ablynx N.V. | Nanobodies and Polypeptides Against EGFR and IGF-IR |
| WO2007042289A2 (en) | 2005-10-11 | 2007-04-19 | Ablynx N.V. | Nanobodies™ and polypeptides against egfr and igf-ir |
| AR056857A1 (es) | 2005-12-30 | 2007-10-24 | U3 Pharma Ag | Anticuerpos dirigidos hacia her-3 (receptor del factor de crecimiento epidérmico humano-3) y sus usos |
| WO2007112940A2 (en) | 2006-03-31 | 2007-10-11 | Ablynx N.V. | Albumin-derived amino acid sequence, use thereof for increasing the half-life of therapeutic proteins and of other therapeutic compounds and entities, and constructs comprising the same |
| EP2010568A1 (en) | 2006-04-14 | 2009-01-07 | Ablynx N.V. | Dp-78-like nanobodies |
| AU2007260787A1 (en) | 2006-06-13 | 2007-12-21 | Zymogenetics, Inc | IL-17 and IL-23 antagonists and methods of using the same |
| TW200815469A (en) | 2006-06-23 | 2008-04-01 | Astrazeneca Ab | Compounds |
| WO2008000279A1 (en) | 2006-06-26 | 2008-01-03 | Aida Centre, S.L. | Blister package integrating rfid based tags |
| GB0612928D0 (en) | 2006-06-29 | 2006-08-09 | Ucb Sa | Biological products |
| EP2057191A1 (en) | 2006-08-18 | 2009-05-13 | Ablynx N.V. | Amino acid sequences directed against il-6r and polypeptides comprising the same for the treatment of deseases and disorders associated with il-6-mediated signalling |
| EP2069402A2 (en) | 2006-09-08 | 2009-06-17 | Ablynx N.V. | Serum albumin binding proteins with long half-lives |
| US7767206B2 (en) | 2006-10-02 | 2010-08-03 | Amgen Inc. | Neutralizing determinants of IL-17 Receptor A and antibodies that bind thereto |
| EP2086998B1 (en) | 2006-10-11 | 2011-12-07 | Ablynx N.V. | Amino acid sequences that bind to serum proteins in a manner that is essentially independent of the ph, compounds comprising the same, and use thereof |
| US20100034194A1 (en) | 2006-10-11 | 2010-02-11 | Siemens Communications Inc. | Eliminating unreachable subscribers in voice-over-ip networks |
| GB0620729D0 (en) * | 2006-10-18 | 2006-11-29 | Ucb Sa | Biological products |
| WO2008068280A1 (en) | 2006-12-05 | 2008-06-12 | Ablynx N.V. | Peptides capable of binding to serum proteins |
| EP2647388A1 (en) | 2007-02-16 | 2013-10-09 | Merrimack Pharmaceuticals, Inc. | Antibodies Against ERBB3 and Uses Thereof |
| US7790676B2 (en) | 2007-03-28 | 2010-09-07 | Zymogenetics, Inc. | Soluble IL-17RA/RC fusion proteins |
| CN101990439A (zh) | 2007-07-06 | 2011-03-23 | 特鲁比昂药品公司 | 具有置于c末端的特异性结合结构域的结合肽 |
| EP2225278A2 (en) | 2007-11-27 | 2010-09-08 | Ablynx N.V. | Amino acid sequences directed against her2 and polypeptides comprising the same for the treatment of cancers and/or tumors |
| WO2009082624A2 (en) | 2007-12-10 | 2009-07-02 | Zymogenetics, Inc. | Antagonists of il-17a, il-17f, and il-23 and methods of using the same |
| CA2712432C (en) | 2008-01-29 | 2018-09-25 | Ablynx N.V. | Methods to stabilize single variable domains |
| US8217140B2 (en) | 2008-04-17 | 2012-07-10 | Ablynx N.V. | Peptides capable of binding to serum proteins and compounds, constructs and polypeptides comprising the same |
| NZ600584A (en) | 2008-05-05 | 2014-05-30 | Novimmune Sa | Anti-il 17a/il-17f cross-reactive antibodies and methods of use thereof |
| JP6034023B2 (ja) | 2008-05-16 | 2016-11-30 | アブリンクス エン．ヴェー． | Ｃｘｃｒ４及び他のｇｐｃｒに指向性を有するアミノ酸配列及びそれを含む化合物 |
| US8790642B2 (en) * | 2008-08-29 | 2014-07-29 | Genentech, Inc. | Cross-reactive and bispecific anti-IL-17A/F antibodies |
| WO2010034443A1 (en) | 2008-09-29 | 2010-04-01 | F. Hoffmann-La Roche Ag | Antibodies against human il 17 and uses thereof |
| RU2015132478A (ru) | 2009-03-05 | 2015-12-10 | Эббви Инк. | Связывающие il-17 белки |
| PT2424889E (pt) | 2009-04-30 | 2015-11-12 | Ablynx Nv | Método de produção de anticorpos de domínio |
| JP6053517B2 (ja) | 2009-05-05 | 2016-12-27 | ノヴィミュンヌ エスア | 抗ｉｌ−１７ｆ抗体およびそれらの使用法 |
| WO2010142551A2 (en) * | 2009-06-12 | 2010-12-16 | Ablynx N.V. | Single variable domain (vhh) antibodies to cytokines of the il-17 receptor family |
| AU2010313304B2 (en) | 2009-10-30 | 2015-08-20 | Janssen Biotech, Inc. | IL-17A antagonists |
| BR112012017150B1 (pt) | 2010-01-15 | 2022-03-03 | Kirin-Amgen Inc | Formulação farmacêutica, recipiente farmacêutico, e kit |
| US8965476B2 (en) * | 2010-04-16 | 2015-02-24 | Sanofi-Aventis Deutschland Gmbh | Tissue penetration device |
| KR101620771B1 (ko) | 2010-10-08 | 2016-05-12 | 노파르티스 아게 | Ｉｌ―17 길항제를 사용하는 건선의 치료 방법 |
| LT3111954T (lt) | 2010-11-05 | 2019-07-10 | Novartis Ag | Ankilozuojančio spondilito gydymo būdai, naudojant anti-il-17 antikūnus |
| CA2823812C (en) | 2011-01-14 | 2017-02-14 | Ucb Pharma S.A. | Antibody molecules which bind il-17a and il-17f |
| TWI439451B (zh) | 2011-03-24 | 2014-06-01 | Hoffmann La Roche | 雜環胺衍生物 |
| UA117218C2 (uk) | 2011-05-05 | 2018-07-10 | Мерк Патент Гмбх | Поліпептид, спрямований проти il-17a, il-17f та/або il17-a/f |
| SG11201401796SA (en) | 2011-10-24 | 2014-10-30 | Abbvie Inc | Bispecific immunobinders directed against tnf and il-17 |
| WO2013150043A1 (en) | 2012-04-05 | 2013-10-10 | F. Hoffmann-La Roche Ag | Bispecific antibodies against human tweak and human il17 and uses thereof |
| AR090626A1 (es) | 2012-04-20 | 2014-11-26 | Lilly Co Eli | Anticuerpos anti-baff-anti-il-17 biespecificos |
| EP4450086A2 (en) | 2013-02-08 | 2024-10-23 | Novartis AG | Anti-il-17a antibodies and their use in treating autoimmune and inflammatory disorders |
| CL2015001213A1 (es) | 2015-05-07 | 2015-07-10 | Pontificia Universidad Católica De Chile | Método ex vivo para predecir respuesta a un tratamiento inmunomodulador en pacientes con enfermedad inflamatoria, el cual comprende la cuantificación de las razones entre las concentraciones de citoquinas seleccionadas de ifn-gamma/il-17f, il17f/il-10, il-17f/ifn-gamma e il-10/il17f; y kit para llevar a cabo el método. |
-
2012
- 2012-04-05 UA UAA201314154A patent/UA117218C2/uk unknown
- 2012-05-04 JP JP2014508842A patent/JP6628965B2/ja active Active
- 2012-05-04 SI SI201231255T patent/SI2705058T1/en unknown
- 2012-05-04 NZ NZ616761A patent/NZ616761A/en unknown
- 2012-05-04 LT LTEP12726593.2T patent/LT2705058T/lt unknown
- 2012-05-04 PT PT127265932T patent/PT2705058T/pt unknown
- 2012-05-04 EP EP22169137.1A patent/EP4105231A1/en active Pending
- 2012-05-04 SG SG10201606409TA patent/SG10201606409TA/en unknown
- 2012-05-04 CN CN201611048984.6A patent/CN107098971B/zh active Active
- 2012-05-04 CA CA2834907A patent/CA2834907C/en active Active
- 2012-05-04 EP EP12726593.2A patent/EP2705058B1/en active Active
- 2012-05-04 BR BR112013028407-2A patent/BR112013028407B1/pt active IP Right Grant
- 2012-05-04 MX MX2013012844A patent/MX2013012844A/es unknown
- 2012-05-04 CN CN201280033175.1A patent/CN103717618B/zh active Active
- 2012-05-04 DK DK12726593.2T patent/DK2705058T3/en active
- 2012-05-04 AU AU2012257942A patent/AU2012257942B8/en active Active
- 2012-05-04 KR KR1020137032085A patent/KR102083230B1/ko active IP Right Grant
- 2012-05-04 EA EA201391632A patent/EA035973B9/ru not_active IP Right Cessation
- 2012-05-04 EP EP18150770.8A patent/EP3363815A1/en active Pending
- 2012-05-04 SG SG2013079371A patent/SG194632A1/en unknown
- 2012-05-04 MY MYPI2013702070A patent/MY167231A/en unknown
- 2012-05-04 ES ES12726593.2T patent/ES2662371T3/es active Active
- 2012-05-04 WO PCT/EP2012/058313 patent/WO2012156219A1/en active Application Filing
- 2012-05-04 HU HUE12726593A patent/HUE037225T2/hu unknown
- 2012-05-04 US US14/115,549 patent/US10017568B2/en active Active
-
2013
- 2013-10-10 IL IL228813A patent/IL228813B/en active IP Right Grant
- 2013-10-25 CL CL2013003090A patent/CL2013003090A1/es unknown
-
2018
- 2018-03-05 HR HRP20180380TT patent/HRP20180380T1/hr unknown
- 2018-05-02 JP JP2018088769A patent/JP6768027B2/ja active Active
- 2018-06-07 US US16/002,135 patent/US10829552B2/en active Active
-
2020
- 2020-05-14 JP JP2020084866A patent/JP7093380B2/ja active Active
- 2020-09-29 US US17/036,602 patent/US11773159B2/en active Active
-
2022
- 2022-02-24 US US17/679,675 patent/US20220195031A1/en active Pending
- 2022-06-17 JP JP2022097718A patent/JP2022137058A/ja active Pending
-
2024
- 2024-05-22 JP JP2024083267A patent/JP2024122989A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2018154628A5 (ja) | ||
| JP2020193195A5 (ja) | ||
| JP2014516945A5 (ja) | ||
| HRP20180380T1 (hr) | Sekvence aminokiseline usmjerene protiv il-17a, il-17f i/ili il17-a/f i polipeptidi koji ih sadrže | |
| JP2017018106A5 (ja) | ||
| JP2010511056A5 (ja) | ||
| JP2010538608A5 (ja) | ||
| HRP20190932T1 (hr) | Molekule protutijela koje se vežu na il-17a i il-17f | |
| JP5502752B2 (ja) | 抗ｍｉｆ抗体 | |
| JP2021072810A (ja) | 可変ドメインｖｌおよびｖｈｈ誘導体に基づく高アフィニティおよび凝集耐性抗体 | |
| JP2019162105A5 (ja) | ||
| JP2009537608A5 (ja) | ||
| JP2009539349A5 (ja) | ||
| JP2011506422A5 (ja) | ||
| JP2012524071A5 (ja) | ||
| JP2017506075A5 (ja) | ||
| JP2020519308A5 (ja) | ||
| IL245001B2 (en) | Antibodies specific to cancer necrosis factor-like ligand 1a and preparations and their uses | |
| RU2011110169A (ru) | Антитела против ccr2 | |
| JP2012512641A5 (ja) | ||
| JP2012517818A5 (ja) | ||
| JP2010162017A5 (ja) | ||
| JP2015504306A5 (ja) | ||
| JP2017510575A5 (ja) | ||
| JP2012524524A5 (ja) |